Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes

  • Gorka Orive
  • , Dwaine Emerich
  • , Ali Khademhosseini
  • , Shinichi Matsumoto
  • , R. M. Hernandez
  • , J. L. Pedraz
  • , Tejal Desai
  • , Riccardo Calafiore
  • , Paul de Vos

Research output: Contribution to journal(Systematic) Review articlepeer-review

Abstract

Encapsulating, or immunoisolating, insulin-secreting cells within implantable, semipermeable membranes is an emerging treatment for type 1 diabetes. This approach can eliminate the need for immunosuppressive drug treatments to prevent transplant rejection and overcome the shortage of donor tissues by utilizing cells derived from allogeneic or xenogeneic sources. Encapsulation device designs are being optimized alongside the development of clinically viable, replenishable, insulin-producing stem cells, for the first time creating the possibility of widespread therapeutic use of this technology. Here, we highlight the status of the most advanced and widely explored implementations of cell encapsulation with an eye toward translating the potential of this technological approach to medical reality.
Original languageEnglish
Pages (from-to)445-456
Number of pages12
JournalTrends in Biotechnology
Volume36
Issue number4
DOIs
Publication statusPublished - Apr 2018
Externally publishedYes

Keywords

  • Alginate-pll capsules
  • L-lysine microcapsules
  • Cell encapsulation
  • Beta-cells
  • Inflammatory responses
  • Human islets
  • Stem-cells
  • Biocompatibility
  • Progenitors
  • Chemistry

Fingerprint

Dive into the research topics of 'Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes'. Together they form a unique fingerprint.

Cite this